ライフサイエンスコーパス: primary pulmonary hypertension

1 l in the general population of patients with primary pulmonary hypertension.

2 as improved survival in patients with severe primary pulmonary hypertension.

3 ated in the study; four had CDH, and one had primary pulmonary hypertension.

4 rotein (BMPR-II) have been shown to underlie primary pulmonary hypertension.

5 ated in tumorigenesis and in the etiology of primary pulmonary hypertension.

6 small pulmonary arteries that is typical of primary pulmonary hypertension.

7 nary hypertension may actually have familial primary pulmonary hypertension.

8 gic features indistinguishable from those of primary pulmonary hypertension.

9 registry of 67 families affected by familial primary pulmonary hypertension.

10 ch has recently been found to cause familial primary pulmonary hypertension.

11 virus HHV-8 may have a pathogenetic role in primary pulmonary hypertension.

12 nol (prostacyclin) in patients with advanced primary pulmonary hypertension.

13 ascular remodeling that is characteristic of primary pulmonary hypertension.

14 oncern are changes in brain biochemistry and primary pulmonary hypertension.

15 mportant cause of morbidity and mortality in primary pulmonary hypertension.

16 In lung tissue from 10 of 16 patients with primary pulmonary hypertension (62 percent), cells withi

17 old) and diseased lung specimens (emphysema, primary pulmonary hypertension) additional HOX genes fro

18 issue samples from 16 patients with sporadic primary pulmonary hypertension and 14 patients with seco

19 Six members affected with familial primary pulmonary hypertension and 6 of 10 at risk for c

20 naling pathway is defective in patients with primary pulmonary hypertension and may implicate the pat

21 ive properties is an effective treatment for primary pulmonary hypertension and pulmonary arterial hy

22 rs as an idiopathic disease (formerly called primary pulmonary hypertension) and as a consequence of

23 nitrogen load, concurrent medical stressors, primary pulmonary hypertension, and hepatic glutamine sy

24 the DiGeorge, Holt-Oram, Alagille, familial primary pulmonary hypertension, and Noonan syndromes.

25 Most patients with primary pulmonary hypertension are thought to have spora

26 dilators, many of which have been studied in primary pulmonary hypertension, are now undergoing study

27 ied by chronic pulmonary thromboembolism and primary pulmonary hypertension, are relatively cryptic i

28 been used successfully to palliate endstage primary pulmonary hypertension but has not been attempte

29 We established the diagnosis of primary pulmonary hypertension by direct evaluation of p

30 prostenol improves survival in patients with Primary Pulmonary Hypertension compared with that predic

31 Each of the eight patients with primary pulmonary hypertension exhibited improvement in

32 Plexiform lesions from patients with primary pulmonary hypertension had a histologic and immu

33 Familial primary pulmonary hypertension has been diagnosed in 18

34 A gene linked to familial primary pulmonary hypertension has recently been mapped

35 Most patients with familial primary pulmonary hypertension have defects in the gene

36 The pathogenesis of primary pulmonary hypertension in human immunodeficiency

37 ize severe pulmonary hypertension (including primary pulmonary hypertension) in humans.

38 Primary pulmonary hypertension is a progressive disease

39 Familial primary pulmonary hypertension is a rare autosomal domin

40 Primary pulmonary hypertension is associated with abnorm

41 Although primary pulmonary hypertension is rare, cases secondary

42 ality of life, and survival in patients with primary pulmonary hypertension, its use in patients with

43 As previously demonstrated in patients with primary pulmonary hypertension, long-term PGI2 may have

44 In primary pulmonary hypertension, long-term therapy with e

45 e transcriptase-polymerase chain reaction in primary pulmonary hypertension lung specimens when compa

46 that many patients with apparently sporadic primary pulmonary hypertension may actually have familia

47 Many cases of apparently sporadic primary pulmonary hypertension may be familial.

48 nal therapy alone in 81 patients with severe primary pulmonary hypertension (New York Heart Associati

49 broplasia [valvular heart disease (VHD)] and primary pulmonary hypertension observed in patients taki

50 syndrome, sepsis, pulmonary hypoplasia, and primary pulmonary hypertension of the newborn.

51 rganization (WHO) functional class II or III primary pulmonary hypertension or PAH related to either

52 We evaluated 27 patients with primary pulmonary hypertension over a mean (+/-SD) perio

53 on (P < 0.001), and lung transplantation for primary pulmonary hypertension (P = 0.045) were associat

54 gh HIV-associated pulmonary hypertension and primary pulmonary hypertension (PPH) are clinically and

55 he pathogenesis is unknown and any link with primary pulmonary hypertension (PPH) has been speculativ

56 Patients with primary pulmonary hypertension (PPH) have a pulmonary va

57 study was to determine whether patients with primary pulmonary hypertension (PPH) have an immunogenet

58 s of experience with vasodilator therapy for primary pulmonary hypertension (PPH) in children.

59 Primary pulmonary hypertension (PPH) is a disease charac

60 Primary pulmonary hypertension (PPH) is a disease of unk

61 Primary pulmonary hypertension (PPH) is a frequently fat

62 Primary pulmonary hypertension (PPH) is a life-threateni

63 Primary pulmonary hypertension (PPH) is a progressive di

64 Primary pulmonary hypertension (PPH) is a rare and fatal

65 Familial primary pulmonary hypertension (PPH) is a rare autosomal

66 Primary pulmonary hypertension (PPH) is a rare disease o

67 Primary pulmonary hypertension (PPH) is a rare disorder

68 Primary pulmonary hypertension (PPH) is a severe and pro

69 Primary pulmonary hypertension (PPH) is characterized by

70 Primary pulmonary hypertension (PPH) is characterized by

71 The pathogenesis of primary pulmonary hypertension (PPH) is unknown, althoug

72 Primary pulmonary hypertension (PPH) may have an autoimm

73 , and subjects with moderate RV failure from primary pulmonary hypertension (PPH) or idiopathic dilat

74 o investigate the responses of patients with primary pulmonary hypertension (PPH) to constant work ra

75 twentieth century, the published reports on primary pulmonary hypertension (PPH) were confined to cl

76 prostacyclin dose reduction in patients with primary pulmonary hypertension (PPH) who developed high

77 lantation) from eight patients with Stage IV primary pulmonary hypertension (PPH) with the reactivity

78 Primary pulmonary hypertension (PPH), an often fatal dis

79 nesis of the vascular lesions characterizing primary pulmonary hypertension (PPH), an often fatal pul

80 4 idiopathic dilated cardiomyopathy (IDC), 8 primary pulmonary hypertension (PPH), and 13 nonfailing

81 ilated cardiomyopathy (IDC), 8 subjects with primary pulmonary hypertension (PPH), and 32 organ donor

82 f prostacyclin is an effective treatment for primary pulmonary hypertension (PPH), and has recently b

83 Primary pulmonary hypertension (PPH), characterized by o

84 de effects, such as cardiac valvulopathy and primary pulmonary hypertension (PPH), limits the clinica

85 lmonary vascular resistance in patients with primary pulmonary hypertension (PPH), right atrial press

86 he lung tissue obtained from 6 patients with primary pulmonary hypertension (PPH)-including 2 patient

87 e with the disease severity of patients with primary pulmonary hypertension (PPH).

88 underlie many familial and sporadic cases of primary pulmonary hypertension (PPH).

89 nd clinical outcomes in patients with severe primary pulmonary hypertension (PPH).

90 underlie many cases of familial and sporadic primary pulmonary hypertension (PPH).

91 E inhibition might be a useful treatment for primary pulmonary hypertension (PPH).

92 the inherited form of the vascular disorder primary pulmonary hypertension (PPH).

93 sidered indistinguishable from idiopathic or primary pulmonary hypertension (PPH).

94 mic response to high-dose oral nifedipine in primary pulmonary hypertension (PPH).

95 hich characterize the vascular remodeling in primary pulmonary hypertension (PPH).

96 d pulmonary artery pressure in patients with primary pulmonary hypertension (PPH).

97 es and the evidence linking fenfluramines to primary pulmonary hypertension (PPH).

98 cases of moderate to severe PH (15 cases of primary pulmonary hypertension [PPH], eight cases of Eis

99 A 22-year-old woman with primary pulmonary hypertension presented with displaceme

100 ary hypertension occurs in 3 distinct forms: primary pulmonary hypertension, pulmonary hypertension o

101 e echocardiographic manifestations of severe primary pulmonary hypertension reflect abnormalities in

102 pproximately 6% of cases recorded in the NIH Primary Pulmonary Hypertension Registry are inherited in

103 edicted by the National Institutes of Health Primary Pulmonary Hypertension Registry's survival equat

104 Failure to detect familial primary pulmonary hypertension results from incomplete e

105 Registry of Primary Pulmonary Hypertension, standardization of nomen

106 Treatment with infusion of prostacyclin for primary pulmonary hypertension was approved, paving the

107 nt of persons carrying the gene for familial primary pulmonary hypertension, we hypothesized that man

108 lung disease that is indistinguishable from primary pulmonary hypertension, we investigated the gene

109 A patient with primary pulmonary hypertension who underwent a technical

110 heart disease and cardiac cirrhosis (1), and primary pulmonary hypertension with primary biliary cirr